We at TIEFEENBACHER PHARMACEUTICALS strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are excited to share that we have successfully prepared the launch of the generic version of Apremilast for a market entry on day one after patent expiration in Canada.

Apremilast is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers. We are standing out in launching the only generic version of Apremilast in the form of a starter kit (10 mg, 20 mg, and 30 mg) additionally to bottles of 30 mg tablets. This allows the product to be taken gradually to the recommended dosage, facilitating the work of physicians and pharmacists and improving the patient experience.

The product has been developed and produced in TIEFENBACHER GROUP´s own state-of-the-art facilities in India and is marketed by our partner, a well-established Canadian pharmaceutical company.

With this early market entry TIEFENBACHER PHARMACEUTICALS achieves significant savings for the international health care systems and enables patients in Canada a better affordable access to a life-improving treatment.

For further information about our pharmaceuticals or medical devices please contact TIEFENBACHER PHARMACEUTICALS: info@aet.eu 

TIEFENBACHER PHARMACEUTICALS is as a part of TIEFENBACHER GROUP – pioneering healthcare since 1963. Please visit us on: www.aet.eu and www.tiefenbachergroup.com